Harbin Pharmaceutical Group Co LtdInnovative drug stocks active; Harbin Pharmaceutical hit fourth consecutive daily limit up, driven by strong out-licensing deal data.
The semiconductor sector tumbled, with Demingli, a storage leader valued at over 100 billion yuan, hitting limit down. Demingli issued a forecast projecting net profit attributable to shareholders of the parent company at 5.7 billion to 6.5 billion yuan for the first half of 2026, while its first-quarter net profit was 3.346 billion yuan. Based on this, second-quarter net profit is estimated to have fallen 5.74% quarter-on-quarter to 2.965 billion yuan. Shares of Muxi, Huatian Technology, and Youyan Silicon fell more than 9%. Innovative drug stocks remained active, with Harbin Pharmaceutical hitting its fourth consecutive daily limit up and Dizal Pharmaceutical surging by the 20% daily limit. Data from the National Medical Products Administration showed that the total value of out-licensing deals for innovative drugs in the first half of the year reached approximately 110 billion US dollars, already accounting for 80% of the full-year total for 2025.
Harbin Pharmaceutical Group Co LtdInnovative drug stocks active; Harbin Pharmaceutical hit fourth consecutive daily limit up, driven by strong out-licensing deal data.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. ADizal Pharmaceutical surged by 20% daily limit, benefiting from the innovative drug sector rally and record out-licensing deal value.
Shenzhen Techwinsemi Technology Co. Ltd.
Tianshui Huatian Technology Co Ltd
GRINM Semiconductor Materials Co. Ltd. A
MetaX Integrated Circuits (Shanghai) Co Ltd